EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Safety of Immune Checkpoint Inhibitors and Clinical Outcomes in Cancer Patients: A Multicenter Study from Saudi Arabia

Ahmed S. Alanazi, Lama Alfehaid, Albatoul Alomran, Manar Alsahli, Reema Alotaibi, Farah Alsaidy, Norah Alqahtani, Mada Alharbi, Eman Alzahrani, Hatoon Bakhribah, Fouad H. AlNajjar, Omar A. Almohammed und 1 weitere

Cancers · 17.11.2026 · 18 (22) · 3679

DOI: 10.3390/cancers18223679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 17.11.2026. Verfasst von Ahmed S. Alanazi und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment but can induce immune-related adverse events (irAEs), and real-world data from Saudi Arabia remain limited. We aimed to characterize the incidence, timing, and predictors of irAEs and their association with survival.

Methods

We conducted a multicenter retrospective cohort study of adults who received at least one ICI dose at two tertiary centers in Riyadh (January 2017–January 2023; follow-up until July 2025). Physician-documented irAEs were extracted from medical records. Predictors were assessed using logistic regression, and progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier methods, with a sensitivity analysis excluding isolated fatigue and a 3-month landmark analysis.

Results

Among 608 patients (median age, 62 years; 55.9% male; 77.1% stage IV), 338 (55.6%) developed at least one irAE, most commonly fatigue (23.8%), endocrine events (15.3%), and skin reactions (10.2%). Median time to irAE onset was 84 days, with endocrine events occurring latest (median, 135 days). Hypertension was independently associated with irAE development (adjusted odds ratio, 1.58; 95% confidence interval, 1.04–2.40). Patients with irAEs had longer median PFS (14.26 vs. 6.08 months; p < 0.0001) and OS (26.14 vs. 16.91 months; p = 0.0324). The PFS association persisted after excluding isolated fatigue, whereas the OS association did not; neither was significant in the landmark analysis.

Conclusions

In this real-world multicenter cohort, irAEs were common and showed distinct organ-specific onset patterns. Their associations with longer PFS and OS were attenuated after accounting for exposure definition and immortal time bias and should not be interpreted as evidence that irAEs predict treatment benefit.

Zitieren

APA

Alanazi, A. S., Alfehaid, L., Alomran, A., Alsahli, M., Alotaibi, R., Alsaidy, F., Alqahtani, N., Alharbi, M., Alzahrani, E., Bakhribah, H., AlNajjar, F. H., Almohammed, O. A., & Alsuhebany, N. (2026). Real-World Safety of Immune Checkpoint Inhibitors and Clinical Outcomes in Cancer Patients: A Multicenter Study from Saudi Arabia. Cancers, 18(22), 3679. https://doi.org/10.3390/cancers18223679

Vancouver

Alanazi AS, Alfehaid L, Alomran A, Alsahli M, Alotaibi R, Alsaidy F, et al. Real-World Safety of Immune Checkpoint Inhibitors and Clinical Outcomes in Cancer Patients: A Multicenter Study from Saudi Arabia. Cancers. 2026;18(22):3679. doi:10.3390/cancers18223679

BibTeX
@article{Alanazi2026,
  author = {Alanazi, Ahmed S. and Alfehaid, Lama and Alomran, Albatoul and Alsahli, Manar and Alotaibi, Reema and Alsaidy, Farah and Alqahtani, Norah and Alharbi, Mada and Alzahrani, Eman and Bakhribah, Hatoon and AlNajjar, Fouad H. and Almohammed, Omar A. and Alsuhebany, Nada},
  title = {Real-World Safety of Immune Checkpoint Inhibitors and Clinical Outcomes in Cancer Patients: A Multicenter Study from Saudi Arabia},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3679},
  doi = {10.3390/cancers18223679}
}
Kostenlos starten →